Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
Infection, Human Immunodeficiency Virus I, HIV Infection
About this trial
This is an interventional trial for Infection, Human Immunodeficiency Virus I focused on measuring protease inhibitor, ritonavir, GW433908, HIV-1, fosamprenavir
Eligibility Criteria
Inclusion criteria: Prior participation in study APV30005 AND one of the following studies: APV30001, APV30002, AZL30006, APV30003. Must be failing virologically (>1000 copies at two consecutive time-points) and have a screening genotype with evidence of at least one new APV-associated protease mutation: V32I (+/- I47V), I50V, I54L/M, I84V acquired since commencing treatment with GW433908. Exclusion criteria: Have 2 or more of the primary resistance mutations D30N, G48V, V82A/F/T/S and L90M. Have a medical need for use of an non-nucleoside reductase transferase inhibitor (NNRTI). Have an acute CDC Class C event requiring therapeutic intervention. Are pregnant or lactating. Have any other condition which in the opinion of the investigator would preclude their participation.
Sites / Locations
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site